Randomized	randomized	O	O
,	,	O	O
double-blind	double-blind	O	O
trial	trial	O	O
of	of	O	O
mazindol	mazindol	S_chemical	O
in	in	O	O
Duchenne	duchenne	O	O
dystrophy	dystrophy	O	O
.	.	O	O

There	there	O	O
is	is	O	O
evidence	evidence	O	O
that	that	O	O
growth	growth	B_chemical	O
hormone	hormone	I_chemical	O
may	may	O	O
be	be	O	O
related	related	O	O
to	to	O	O
the	the	O	O
progression	progression	O	O
of	of	O	O
weakness	weakness	O	S_disease
in	in	O	O
Duchenne	duchenne	O	O
dystrophy	dystrophy	O	O
.	.	O	O

We	we	O	O
conducted	conducted	O	O
a	a	O	O
12-month	12-month	O	O
controlled	controlled	O	O
trial	trial	O	O
of	of	O	O
mazindol	mazindol	S_chemical	O
,	,	O	O
a	a	O	O
putative	putative	O	O
growth	growth	B_chemical	O
hormone	hormone	I_chemical	O
secretion	secretion	O	O
inhibitor	inhibitor	O	O
,	,	O	O
in	in	O	O
83	83	O	O
boys	boys	O	O
with	with	O	O
Duchenne	duchenne	O	O
dystrophy	dystrophy	O	O
.	.	O	O

Muscle	muscle	O	O
strength	strength	O	O
,	,	O	O
contractures	contractures	O	O
,	,	O	O
functional	functional	O	O
ability	ability	O	O
and	and	O	O
pulmonary	pulmonary	O	B_disease
function	function	O	I_disease
were	were	O	O
tested	tested	O	O
at	at	O	O
baseline	baseline	O	O
,	,	O	O
and	and	O	O
6	6	O	O
and	and	O	O
12	12	O	O
months	months	O	O
after	after	O	O
treatment	treatment	O	O
with	with	O	O
mazindol	mazindol	S_chemical	O
(	(	O	O
3	3	O	O
mg/d	mg/d	O	O
)	)	O	O
or	or	O	O
placebo	placebo	O	O
.	.	O	O

The	the	O	O
study	study	O	O
was	was	O	O
designed	designed	O	O
to	to	O	O
have	have	O	O
a	a	O	O
power	power	O	O
of	of	O	O
greater	greater	O	O
than	than	O	O
0.90	0.90	O	O
to	to	O	O
detect	detect	O	O
a	a	O	O
slowing	slowing	O	O
to	to	O	O
25	25	O	O
%	%	O	O
of	of	O	O
the	the	O	O
expected	expected	O	O
rate	rate	O	O
of	of	O	O
progression	progression	O	O
of	of	O	O
weakness	weakness	O	S_disease
at	at	O	O
P	p	O	O
less	less	O	O
than	than	O	O
0.05	0.05	O	O
.	.	O	O

Mazindol	mazindol	S_chemical	O
did	did	O	O
not	not	O	O
benefit	benefit	O	O
strength	strength	O	O
at	at	O	O
any	any	O	O
point	point	O	O
in	in	O	O
the	the	O	O
study	study	O	O
.	.	O	O

Side	side	O	O
effects	effects	O	O
attributable	attributable	O	O
to	to	O	O
mazindol	mazindol	S_chemical	O
included	included	O	O
decreased	decreased	O	O
appetite	appetite	O	O
(	(	O	O
36	36	O	O
%	%	O	O
)	)	O	O
,	,	O	O
dry	dry	O	B_disease
mouth	mouth	O	I_disease
(	(	O	O
10	10	O	O
%	%	O	O
)	)	O	O
,	,	O	O
behavioral	behavioral	O	O
change	change	O	O
(	(	O	O
22	22	O	O
%	%	O	O
)	)	O	O
,	,	O	O
and	and	O	O
gastrointestinal	gastrointestinal	O	O
symptoms	symptoms	O	O
(	(	O	O
18	18	O	O
%	%	O	O
)	)	O	O
;	;	O	O
mazindol	mazindol	S_chemical	O
dosage	dosage	O	O
was	was	O	O
reduced	reduced	O	O
in	in	O	O
43	43	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
.	.	O	O

The	the	O	O
effect	effect	O	O
of	of	O	O
mazindol	mazindol	S_chemical	O
on	on	O	O
GH	gh	O	O
secretion	secretion	O	O
was	was	O	O
estimated	estimated	O	O
indirectly	indirectly	O	O
by	by	O	O
comparing	comparing	O	O
the	the	O	O
postabsorptive	postabsorptive	O	O
IGF-I	igf-i	O	O
levels	levels	O	O
obtained	obtained	O	O
following	following	O	O
3	3	O	O
,	,	O	O
6	6	O	O
,	,	O	O
9	9	O	O
,	,	O	O
and	and	O	O
12	12	O	O
months	months	O	O
in	in	O	O
the	the	O	O
mazindol	mazindol	S_chemical	O
treated	treated	O	O
to	to	O	O
those	those	O	O
in	in	O	O
the	the	O	O
placebo	placebo	O	O
groups	groups	O	O
.	.	O	O

Although	although	O	O
mazindol-treated	mazindol-treated	O	O
patients	patients	O	O
gained	gained	O	O
less	less	O	O
weight	weight	O	O
and	and	O	O
height	height	O	O
than	than	O	O
placebo-treated	placebo-treated	O	O
patients	patients	O	O
,	,	O	O
no	no	O	O
significant	significant	O	O
effect	effect	O	O
on	on	O	O
IGF-I	igf-i	O	O
levels	levels	O	O
was	was	O	O
observed	observed	O	O
.	.	O	O

Mazindol	mazindol	S_chemical	O
doses	doses	O	O
not	not	O	O
slow	slow	O	O
the	the	O	O
progression	progression	O	O
of	of	O	O
weakness	weakness	O	S_disease
in	in	O	O
Duchenne	duchenne	O	O
dystrophy	dystrophy	O	O
.	.	O	O

